Global Monkeypox Vaccine Market Statistics: USD 421.8 Million Value by 2032

Summary:

• The global monkeypox vaccine market size reached USD 86.6 Million in 2023.

• The market is expected to reach USD 421.8 Million by 2032, exhibiting a growth rate (CAGR) of 18.85% during 2024-2032.

• North America leads the market, accounting for the largest monkeypox vaccine market share.

• Based on the type, the market has been bifurcated into replication-competent and replication-deficient.

• Hospital pharmacy accounts for the majority of the market share owing to the wide range of medications available.

• The rise in international focus on infectious diseases is driving the demand for vaccines against emerging threats like monkeypox.

• The noticeable increase in monkeypox cases across multiple regions globally is supporting the growth of the market.

Industry Trends and Drivers:

• Global Health Initiatives and Funding Increases:

The rise in international focus on infectious diseases is driving the demand for vaccines against emerging threats like monkeypox. Governments, global health bodies, and private entities are increasingly investing in vaccine development and distribution frameworks to prevent widespread outbreaks. This rise in funding not only facilitates the accelerated development and approval of new vaccines but also enhances the manufacturing capabilities of pharmaceutical companies. As a result, the capacity to produce vaccines at scale and the ability to rapidly respond to emerging health crises are markedly improving.

• Rising Incidence of Monkeypox Cases:

The noticeable increase in monkeypox cases across multiple regions globally is supporting the growth of the market. This uptick is linked to several factors, including greater human interaction with animal vectors and international travel, which facilitates the cross-border transmission of the virus. The growing awareness among public health authorities and surveillance of monkeypox are leading to improved diagnosis rates, subsequently increasing the perceived need for vaccination. The urgent demand for effective preventive measures against a potential outbreak encourages healthcare systems and governments to procure and stockpile adequate vaccine supplies.

• Advancements in Vaccine Technology:

Recent technological advancements in vaccine research and development (R&D) are bolstering the market growth. Innovations, such as messenger ribonucleic acid (mRNA) vaccine technology, are being adapted for other infectious diseases, including monkeypox. These technologies allow for quicker development and potentially more effective vaccines, increasing their adoption rate. Moreover, the ability to adjust existing platforms to target new pathogens reduces the time and cost associated with vaccine development, making the process more efficient and scalable. This factor not only enhances the production capacity of vaccine manufacturers but also improves the global readiness to combat emerging infectious diseases.

Request for a sample copy of this report: https://www.imarcgroup.com/monkeypox-vaccine-market/requestsample

Monkeypox Vaccine Market Report Segmentation:

By Type:

• Replication-competent

• Replication-deficient

Based on the type, the market has been bifurcated into replication-competent and replication-deficient.

By Route of Administration:

• Subcutaneous
• Percutaneous

Subcutaneous represents the largest segment as it is relatively easy to administer, requiring less skill than intramuscular injections.

By Distribution Channel:

• Hospital Pharmacy

• Retail Pharmacy

• Online Pharmacy

• Others

Hospital pharmacy accounts for the majority of the market share owing to the wide range of medications available.

By End User:

• Hospitals

• Clinics

• Others

Hospitals hold the biggest market share due to the rising number of patients seeking effective healthcare to treat monkey pox.

Regional Insights:

• North America (United States, Canada)
• Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
• Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
• Latin America (Brazil, Mexico, Others)
• Middle East and Africa

North America’s dominance in the monkeypox vaccine market is attributed to investment in drug research operations, leading to advanced technological developments in this field.

If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.

About Us:

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact Us:

IMARC Group

134 N 4th St. Brooklyn, NY 11249, USA

Email: sales@imarcgroup.com

Tel No:(D) +91 120 433 0800

United States: +1-631-791-1145 | United Kingdom: +44-753-713-2163